With all the noise today, could it be that ALKS has the most to lose here? I wonder because it's ALKS tech that permits the timed-release (broadly speaking) in the bloodstream. Presumably, it is this tech which led AMLN to rely on the Byetta data; the tech keeps Byetta "encapsulated", and thus not doing CV harm, until it is released. FDA doesn't believe that circulating Byetta, even with ALKS tech, is CV neutral.
Is there any reason to believe that AMLN was right, and FDA wrong?